Brain Assessment Articles & Analysis: Older
16 news found
The trial will use CDM® technology to assess the efficacy of XPro™ compared with placebo on grey matter integrity in patients with mild AD. ...
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. ...
In as little as 30 seconds after a Swoop scan, advanced artificial intelligence applications analyze and return annotated, segmented brain images, providing clinicians with quantitative markers for decision support and immediate feedback for diagnostic insight. ...
“In the ED, where millions of head injured patients first seek care each year, BrainScope is the only system that aids in the full spectrum assessment of mild traumatic brain injuries including brain bleeds and concussion. ...
Brain-assessment device innovator BrainScope, and Aon plc (NYSE: AON), a leading global professional services firm, today announced the completion of an intellectual property-based funding arrangement. ...
This project, led by Oxford Brain Diagnostics and Dr Nakajima, will gather real world MRI patient data, and will use CDM analysis, based on changes at the cellular level, to assess dementia disease severity and potentially support differential diagnosis. ...
The Concussion Index is the first physiological marker of concussive injury that aids clinicians in the objective assessment of patients at baseline, point of injury, and through recovery. The Concussion Index adds to the suite of FDA cleared algorithms already available on the BrainScope device and in clinical use today to rapidly triage suspected mild traumatic ...
The Bethesda, Maryland based company is helping hospital Emergency Departments (EDs) objectively triage the almost five million patients that present each year with suspected mild traumatic brain injuries. BrainScope’s FDA-cleared decision support tool provides a rapid and accurate assessment of the likelihood of a brain bleed and a ...
“We are extremely pleased with the outcome of this study, demonstrating the promise of the Concussion Index as an objective marker in the clinical assessment of concussion. Importantly, the study targeted patients of high school and college age who are at great risk for both short and long term consequences of concussion, as the brain in still developing," ...
In her new role, Hertzberg will drive the global strategy and commercialization of BrainScope’s traumatic brain injury (TBI) and concussion tools in the traditional healthcare, military and sports arenas and will expand the platform capabilities of its signature product Brainscope One to include objective assessments for brain diseases like ...
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that researchers have published preliminary results related to a multi-modal concussion assessment capability for potential severity and likelihood of prolonged recovery from concussions. ...
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has received FDA clearance to include additional language in its product’s Indications for Use (IFU), adding key terminology related to “multi-modal, multi-parameter assessment" of ...
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it has fulfilled orders for over 170 BrainScope One handheld devices and over 7,500 individual patient headsets to U.S. ...
The companies in the third cohort of the Lazaridis Scale-Up Program include Altus Assessments, Applied Brain Research, Blue J Legal, Jane App, Needls, Sofdesk, TinyEYE, VanHack, and Vive Crop Protection. ...
BrainScope today announced that it has been awarded a research contract by the United States Department of Defense (DOD) valued at $4.5 million to create and integrate ocular capabilities into its handheld, multi-parameter mild Traumatic Brain Injury (mTBI) and concussion products. BrainScope’s initial product in the market, BrainScope One, is the first FDA-cleared ...
BrainScope One is the first FDA-cleared medical device to offer capabilities to assess the full spectrum of brain injury – from concussions (functional abnormality) to brain bleeds (structural injury). ...